Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073762 | 0.84 | LMNA (0.55) | CTSSCTSLLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL13073758 | 0.84 | LMNA (0.55) | CTSSCTSLLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL6414194 | 0.82 | HTT (0.48) | CTSSCTSLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL6416830 | 0.82 | TGM2 (0.46) | CA1CASP1CTSSCTSLLMNA | |
| SCHEMBL2908454 | 0.81 | MTNR1A (0.55) | CA1CTSSCTSLCA2ACHE | |
| SCHEMBL9765305 | 0.80 | LMNA (0.51) | CTSSCTSLLMNASMN1; SMN2SYK | |
| SCHEMBL6414878 | 0.78 | CA1 (0.54) | CA1CASP1CTSSCTSLCA2 | |
| SCHEMBL220633 | 0.78 | LMNA (0.51) | CA1CTSSCTSLLMNASMN1; SMN2 | |
| SCHEMBL5323605 | 0.78 | BCL9 (0.47) | CTSSCTSLPPARGSYKCTSB | |
| SCHEMBL3805427 | 0.76 | LMNA (0.52) | CA1CASP1CTSSCTSLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | CA1 1563/4885CASP1 323/4885CTSS 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.